
RESULTS OF EXTRAORDINARY GENERAL MEETING

The Board of Directors of Pharmesis International Ltd. (the “**Company**”) wishes to announce that at the Extraordinary General Meeting (“**EGM**”) of the Company held on 26 April 2019, the resolution relating to matters set out in the Notice of EGM dated 11 April 2019 was duly passed by way of poll.

The information as required under Rule 704 (16) of the Listing Manual of the Singapore Exchange Securities Trading Limited is as set out below:

Ordinary Resolution number and details	Total number of shares represented by votes for and against the relevant resolution	For		Against	
		Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)
Resolution 1 Proposed Acquisition of 30% Equity Interest in Sichuan Longlife Pharmaceutical Co., Ltd as a major transaction	8,256,300	8,256,300	100%	0	0%

Details of parties who are required to abstain from voting on any resolution(s)

Top Entrepreneur Limited, who holds 2,281,200 ordinary shares in the Company, had abstained from voting on Resolution 1.

Name of firm and/or person appointed as scrutineer

Corporate Backoffice Pte. Ltd. was appointed as the Scrutineer for the EGM.

BY ORDER OF THE BOARD

Wu Xuedan
 Executive Director and Chief Executive Officer
 26 April 2019